Amino ceramide-like compounds and therapeutic methods of use
First Claim
Patent Images
1. A compound comprising D-t-3′
- ,4′
-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol and functional homologues, isomers and pharmaceutically acceptable salts thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Novel amino ceramide-like compounds (1) are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.
52 Citations
17 Claims
-
1. A compound comprising D-t-3′
- ,4′
-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol and functional homologues, isomers and pharmaceutically acceptable salts thereof.
- ,4′
-
2. A compound comprising D-t4′
- -hydroxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol and functional homologues, isomers and pharmaceutically acceptable salts thereof.
-
3. A composition comprising a compound selected from the group consisting of D-t-3′
- ,4′
-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol, D-t-4′
-hydroxy-1-phenyl 2-palmitoylamino-3-pyrrolidino-1-propanol, and functional homologues, isomers and pharmaceutically acceptable salts thereof. - View Dependent Claims (4, 5, 6, 7)
- ,4′
-
8. A method for inhibiting the growth of cancer cells in a mammal, wherein said cancer cells are sensitive to the compounds below, comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising a compound selected from the group consisting of D-t-3′
- ,4′
-ethylenedioxy-1-pheny)-2-palmitoylamino-3-pyrrolidino-1-propanol, D-t4′
-hydroxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol and functional homologues, isomers and pharmaceutically acceptable salts thereof. - View Dependent Claims (9)
- ,4′
-
10. A method for treating a patient having sphingolipidosis by reducing glycosphingolipid synthesis comprising the step of administering to the patient a therapeutically effective amount of a composition comprising a compound selected from the group consisting of D-t-3′
- ,4′
-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol, D-t-4-hydroxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol and functional homologues, isomers and pharmaceutically acceptable salts thereof. - View Dependent Claims (11, 12, 13)
- ,4′
-
14. A method for treating a patient having a microbial or viral infection comprising the step of administering to the patient a therapeutically effective amount of a composition comprising a compound selected from the group consisting of D-t-3′
- ,4′
-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol, D-t-4-hydroxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol and functional homologues, isomers and pharmaceutically acceptable salts thereof.
- ,4′
-
15. A method for treating a patient having a drug resistant tumor sensitive to the compounds below, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising a compound selected from the group consisting of D-t-3′
- ,4′
-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol, D-t-4-hydroxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol and functional homologues, isomers and pharmaceutically acceptable salts thereof.
- ,4′
-
16. A method for reducing tumor angiogenesis in a patient, wherein said angiogenesis is sensitive to the compounds below, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising a compound selected from the group consisting of D-t-3′
- ,4′
-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol, D-t4-hydroxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol and functional homologues, isomers and pharmaceutically acceptable salts thereof.
- ,4′
-
17. A vaccination method comprising the steps of:
-
a) removing cancer cells sensitive to the compounds below, from a patient;
b) treating the cancer cells in vitro with an effective amount of a composition comprising a compound selected from the group consisting of D-t-3′
,4′
-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol, D-t4-hydroxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol andfunctionalhomologues, isomers and pharmaceutically acceptable salts thereof; and
c) administering treated cells to the patient.
-
Specification